Avacta Group Plc

Avacta did not provide revenue or EPS figures on this call; as a clinical-stage biotech, management said it does not yet generate revenues. FY2025 R&D expenses were GBP 18.8 million, up from GBP 14.3 million last year, and administrative expenses fell to about GBP 10 million from GBP 12 million. Net operating cash outflows from continuing operations were GBP 22.64 million versus GBP 24.94 million in 2024. Cash at the end of April was GBP 16.4 million following an oversubscribed GBP 10 million placing and subscription, and management said this extends runway into early Q1 2027. Forward, AVA6103 initial Phase I data are expected by the end of 2026, AVA6000 data updates are expected at ASCO and BIO in the first half of 2026, and Gen Three payload selection/clinical candidate selection are expected in the second half of 2026.

Christina Coughlin framed Avacta as a pure-play oncology company centered on the pre|CISION platform, emphasizing that FAP is expressed in 90% of solid tumors and that the platform could reduce toxicity by concentrating drug in the tumor. She repeatedly stressed execution discipline, saying the company has done what it said it would do on time, and described the next 9 to 12 months as potentially transformative. Her tone was confident and forward-looking, while still acknowledging that key clinical and partnering milestones remain ahead.

Brian Hahn said the top priority is a sustainable long-term financing strategy. He cited FY2025 R&D spend of GBP 18.8 million versus GBP 14.3 million a year earlier, admin expense of about GBP 10 million versus GBP 12 million, and operating cash outflows of GBP 22.64 million versus GBP 24.94 million in 2024. He said cash was GBP 16.4 million at end-April after a GBP 10 million raise, and the runway into early Q1 2027 excludes any partnering income. He also declined to quantify monthly burn and said any bond conversion decisions rest with bondholders.

Analysts focused on AVA6103 enrollment pace, site openings, dosing, and why U.K. centers are not planned; management said recruitment is going well, more U.S. sites are opening, the initial starting dose was agreed with the FDA, and the choice to run the trial in the U.S. was driven by speed, cost, and single-regulator alignment. On AVA6000, questions centered on when Phase II could begin, whether dosing might become indication-specific, and whether an expedited FDA pathway or accelerated approval had been pursued; management said no approval has been sought, the pivotal study will only start with a partner, and the company is still waiting for mature survival and biopsy data. In business development questions, management said partnering discussions are constructive and progressing but remain confidential, while AVA70100/Affimer drug conjugate work has been held because pre|CISION alone is performing well and a biologic half-life extension is no longer needed.